Lab Asset and Facility Management in Pharma Summit Europe

Not only has the pandemic fuelled life science investment, but it has also made us realise the importance of seamless R and D operations and lab facility requirements. Over the last 2 years we have seen huge investments into expanding R and D infrastructure within Europe; including a new £500m new biocluster in Canary Wharf in London, Velo3D opening a new European technical centre in Germany and the LabConnect announcement of increasing their footprint in Europe. Amidst these investments and expansion plans in the LS sector, Lab Operations, R and D Asset and Facility leaders in biopharma are playing an increasingly vital role to ensure internal capabilities and external supplier management are fit-for-purpose to support their scientific teams and R and D pipeline progression.